The Commission proposes to revise the EU’s pharmaceutical legislation – the largest reform in over 20 years – to make it more agile, flexible, and adapted to the needs of citizens and businesses across the EU. The revision will make medicines more available, accessible and affordable. It will support innovation and boost the competitiveness and attractiveness of the EU pharmaceutical […]
H2020. New approaches for clinical management and prevention of resistant bacterial infections in high prevalence settings
Antimicrobial resistance represents a serious threat to public health in Europe and beyond. Within the last decades resistance has increased considerably in many clinically important pathogenic bacteria. The challenge is to address this threat via a multi-disciplinary approach by developing suitable clinical management and infection prevention plans detailing how to deal with resistant bacterial infections […]
H2020. ERA-NET to support the Joint Programming Initiative on Antimicrobial resistance (JPIAMR)
Antimicrobial resistance (AMR) is a serious challenge that has reached alarming levels in the EU and globally. There is an urgent need to address this major health threat by actions that should include boosting research and innovation as well as strengthening coordination and cooperation in this area Scope Proposals should: pool the necessary financial resources […]